These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23041575)

  • 21. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts--role of late sodium current and intracellular ion accumulation.
    Sossalla S; Wagner S; Rasenack EC; Ruff H; Weber SL; Schöndube FA; Tirilomis T; Tenderich G; Hasenfuss G; Belardinelli L; Maier LS
    J Mol Cell Cardiol; 2008 Jul; 45(1):32-43. PubMed ID: 18439620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Late sodium current inhibition alone with ranolazine is sufficient to reduce ischemia- and cardiac glycoside-induced calcium overload and contractile dysfunction mediated by reverse-mode sodium/calcium exchange.
    Soliman D; Wang L; Hamming KS; Yang W; Fatehi M; Carter CC; Clanachan AS; Light PE
    J Pharmacol Exp Ther; 2012 Nov; 343(2):325-32. PubMed ID: 22879384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Na+ current on excitation-contraction coupling in ventricular myocytes of guinea pig heart.
    Janiak R; Lewartowski B
    J Physiol Pharmacol; 1997 Jun; 48(2):159-77. PubMed ID: 9223021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natural History and Risk Stratification in Andersen-Tawil Syndrome Type 1.
    Mazzanti A; Guz D; Trancuccio A; Pagan E; Kukavica D; Chargeishvili T; Olivetti N; Biernacka EK; Sacilotto L; Sarquella-Brugada G; Campuzano O; Nof E; Anastasakis A; Sansone VA; Jimenez-Jaimez J; Cruz F; Sánchez-Quiñones J; Hernandez-Afonso J; Fuentes ME; Średniawa B; Garoufi A; Andršová I; Izquierdo M; Marinov R; Danon A; Expósito-García V; Garcia-Fernandez A; Muñoz-Esparza C; Ortíz M; Zienciuk-Krajka A; Tavazzani E; Monteforte N; Bloise R; Marino M; Memmi M; Napolitano C; Zorio E; Monserrat L; Bagnardi V; Priori SG
    J Am Coll Cardiol; 2020 Apr; 75(15):1772-1784. PubMed ID: 32299589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism of U wave and polymorphic ventricular tachycardia in a canine tissue model of Andersen-Tawil syndrome.
    Morita H; Zipes DP; Morita ST; Wu J
    Cardiovasc Res; 2007 Aug; 75(3):510-8. PubMed ID: 17531215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Altered Na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium.
    Sossalla S; Kallmeyer B; Wagner S; Mazur M; Maurer U; Toischer K; Schmitto JD; Seipelt R; Schöndube FA; Hasenfuss G; Belardinelli L; Maier LS
    J Am Coll Cardiol; 2010 May; 55(21):2330-42. PubMed ID: 20488304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Electrocardiogram in Andersen-Tawil syndrome. New electrocardiographic criteria for diagnosis of type-1 Andersen-Tawil syndrome.
    Kukla P; Biernacka EK; Baranchuk A; Jastrzebski M; Jagodzinska M
    Curr Cardiol Rev; 2014 Aug; 10(3):222-8. PubMed ID: 24827800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinctive electrophysiological characteristics of right ventricular out-flow tract cardiomyocytes.
    Lu YY; Chung FP; Chen YC; Tsai CF; Kao YH; Chao TF; Huang JH; Chen SA; Chen YJ
    J Cell Mol Med; 2014 Aug; 18(8):1540-8. PubMed ID: 24913286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine.
    Maier LS
    J Cardiovasc Pharmacol; 2009 Oct; 54(4):279-86. PubMed ID: 19333133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ranolazine attenuates hypoxia- and hydrogen peroxide-induced increases in sodium channel late openings in ventricular myocytes.
    Ma J; Song Y; Shryock JC; Hu L; Wang W; Yan X; Zhang P; Belardinelli L
    J Cardiovasc Pharmacol; 2014 Jul; 64(1):60-8. PubMed ID: 24705174
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of ranolazine, a novel anti-anginal drug, on ion currents and membrane potential in pituitary tumor GH(3) cells and NG108-15 neuronal cells.
    Chen BS; Lo YC; Peng H; Hsu TI; Wu SN
    J Pharmacol Sci; 2009 Jul; 110(3):295-305. PubMed ID: 19609066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of flecainide for ventricular arrhythmias in patients with Andersen-Tawil syndrome with KCNJ2 mutations.
    Miyamoto K; Aiba T; Kimura H; Hayashi H; Ohno S; Yasuoka C; Tanioka Y; Tsuchiya T; Yoshida Y; Hayashi H; Tsuboi I; Nakajima I; Ishibashi K; Okamura H; Noda T; Ishihara M; Anzai T; Yasuda S; Miyamoto Y; Kamakura S; Kusano K; Ogawa H; Horie M; Shimizu W
    Heart Rhythm; 2015 Mar; 12(3):596-603. PubMed ID: 25496985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Late na(+) current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model.
    Antoons G; Oros A; Beekman JD; Engelen MA; Houtman MJ; Belardinelli L; Stengl M; Vos MA
    J Am Coll Cardiol; 2010 Feb; 55(8):801-9. PubMed ID: 20170820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The antianginal agent ranolazine is a potent antiarrhythmic agent that reduces ventricular arrhythmias: through a mechanism favoring inhibition of late sodium channel.
    Kloner RA; Dow JS; Bhandari A
    Cardiovasc Ther; 2011 Aug; 29(4):e36-41. PubMed ID: 20626400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias.
    Belardinelli L; Liu G; Smith-Maxwell C; Wang WQ; El-Bizri N; Hirakawa R; Karpinski S; Li CH; Hu L; Li XJ; Crumb W; Wu L; Koltun D; Zablocki J; Yao L; Dhalla AK; Rajamani S; Shryock JC
    J Pharmacol Exp Ther; 2013 Jan; 344(1):23-32. PubMed ID: 23010360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tetrodotoxin-Sensitive Neuronal-Type Na
    Munger MA; Olğar Y; Koleske ML; Struckman HL; Mandrioli J; Lou Q; Bonila I; Kim K; Ramos Mondragon R; Priori SG; Volpe P; Valdivia HH; Biskupiak J; Carnes CA; Veeraraghavan R; Györke S; Radwański PB
    J Am Heart Assoc; 2020 Jun; 9(11):e015119. PubMed ID: 32468902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine.
    Belardinelli L; Shryock JC; Fraser H
    Heart; 2006 Jul; 92 Suppl 4(Suppl 4):iv6-iv14. PubMed ID: 16775092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term nerve excitability changes by persistent Na+ current blocker ranolazine.
    Nodera H; Rutkove SB
    Neurosci Lett; 2012 Aug; 524(2):101-6. PubMed ID: 22824305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diastolic transient inward current in long QT syndrome type 3 is caused by Ca2+ overload and inhibited by ranolazine.
    Lindegger N; Hagen BM; Marks AR; Lederer WJ; Kass RS
    J Mol Cell Cardiol; 2009 Aug; 47(2):326-34. PubMed ID: 19371746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ranolazine stabilizes cardiac ryanodine receptors: a novel mechanism for the suppression of early afterdepolarization and torsades de pointes in long QT type 2.
    Parikh A; Mantravadi R; Kozhevnikov D; Roche MA; Ye Y; Owen LJ; Puglisi JL; Abramson JJ; Salama G
    Heart Rhythm; 2012 Jun; 9(6):953-60. PubMed ID: 22245792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.